Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Sunshine Biopharma (SBFM) over the last 14 years, with Q3 2025 value amounting to $31.5 million.

  • Sunshine Biopharma's Liabilities and Shareholders Equity rose 475.95% to $31.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $123.2 million, marking a year-over-year increase of 387.56%. This contributed to the annual value of $30.6 million for FY2024, which is 1175.06% up from last year.
  • Latest data reveals that Sunshine Biopharma reported Liabilities and Shareholders Equity of $31.5 million as of Q3 2025, which was up 475.95% from $32.0 million recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Liabilities and Shareholders Equity registered a high of $42.0 million during Q2 2022, and its lowest value of $1.8 million during Q2 2021.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $29.2 million (2025), whereas its average is $24.1 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first soared by 281808.19% in 2021, then plummeted by 3234.25% in 2023.
  • Over the past 5 years, Sunshine Biopharma's Liabilities and Shareholders Equity (Quarter) stood at $2.2 million in 2021, then surged by 1227.52% to $29.2 million in 2022, then fell by 6.49% to $27.3 million in 2023, then increased by 11.75% to $30.6 million in 2024, then rose by 3.03% to $31.5 million in 2025.
  • Its last three reported values are $31.5 million in Q3 2025, $32.0 million for Q2 2025, and $29.2 million during Q1 2025.